Results 11 to 20 of about 66,449 (275)

Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer

Molecular Cancer, 2022
Background Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resistance to gemcitabine severely limits the effectiveness of this chemotherapy, and the underlying mechanism of gemcitabine ...
Jianyou Gu, Wenjie Huang, Xianxing Wang, Junfeng Zhang, Tian Tao, Yao Zheng, Songsong Liu, Jiali Yang, Zhe-Sheng Chen, Chao-Yun Cai, Jinsui Li, Huaizhi Wang, Yingfang Fan   +12 more
doaj   +2 more sources

cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis [PDF]

Cell Death and Disease
Resistance to gemcitabine in pancreatic ductal adenocarcinoma (PDAC) leads to ineffective chemotherapy and, consequently, delayed treatment, thereby contributing to poor prognosis. Glycolysis is an important intrinsic reason for gemcitabine resistance as
Ge Li, Fei-Fei She, Cheng-Yu Liao, Zu-Wei Wang, Yi-Ting Wang, Yong-Din Wu, Xiao-Xiao Huang, Cheng-Ke Xie, Hong-Yi Lin, Shun-Cang Zhu, Yin-Hao Chen, Zhen-heng Wu, Jiang-Zhi Chen, Shi Chen, Yan-Ling Chen   +14 more
doaj   +2 more sources

Promising molecular mechanisms responsible for gemcitabine resistance in cancer

Genes & Diseases, 2015
Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma (PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good initial response to gemcitabine-based chemotherapy but would eventually develop resistance.
Jia, Yanfei, Xie, Jingwu
openaire   +4 more sources

Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma. [PDF]

Oncol Res
Kidoikhammouan S, Saengboonmee C, Wongkham S, Seubwai W.   +3 more
europepmc   +2 more sources

Study of the Efficacy and Multidrug Resistance Using Gold Nanoparticles-Based Drug Delivery Versus Conventional Chemotherapy in Non-Small-Cell Lung Cancer Cell Line [PDF]

Research in Oncology, 2021
Background: Cisplatin is the main chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) combined with gemcitabine or other agents. Aim: The aim of this study was to evaluate in vitro the anti-tumor efficacy and multidrug resistance of gold
Aida A. Guemei, Eman Dessouky, Thanaa I. Shalaby, Sarah K. Amer, Rasha Nassra   +4 more
doaj   +1 more source

APOBEC3 upregulation drives gemcitabine resistance. [PDF]

Nat Cancer
Maciejowski J, Mohamed T.
europepmc   +3 more sources

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

Cancer Biology & Medicine, 2023
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery.
Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yang Liu, Xiaoqing Ma, Jinsheng Ding, Shengyu Yang, Ran Zhao, Antao Chang, Chuntao Gao, Jing Liu, Tiansuo Zhao, Xiuchao Wang, Chongbiao Huang, Song Gao, Ying Ma, Bo Tang, Yukuan Feng, Hongwei Wang, Jihui Hao   +19 more
doaj   +1 more source

WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition

Drug Discoveries & Therapeutics, 2022
Gemcitabine is widely used in the clinic as a first-line antitumor agent. However, intrinsic and acquired resistance hinders its wide clinical application. In this study, a gemcitabine prodrug nominated as WRQ-2 was designed and synthesized by conjugating gemcitabine with the indole-3-methanol analogue OSU-A9 through a carbamate linkage.
Ruquan, Wang, Yongliang, Li, Jianjun, Gao, Yepeng, Luan   +3 more
openaire   +2 more sources

Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer

Cell Death and Disease, 2021
The poor prognosis of pancreatic cancer is primarily due to the development of resistance to therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been shown to interact with enhancer of zeste 2 polycomb repressive complex 2 ...
Yan Sun, Dianyun Ren, Yingke Zhou, Jian Shen, Heshui Wu, Xin Jin   +5 more
doaj   +1 more source

Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner

Biomedicines, 2022
Treatment of pancreatic ductal adenocarcinoma (PDAC), a dismal disease with poor survival rates, is hampered by the high prevalence of chemotherapy resistance.
C. Arnold Spek, Hella L. Aberson, JanWillem Duitman   +2 more
doaj   +1 more source